These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18588281)

  • 1. Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
    Cappellacci L; Franchetti P; Vita P; Petrelli R; Lavecchia A; Jayaram HN; Saiko P; Graser G; Szekeres T; Grifantini M
    J Med Chem; 2008 Jul; 51(14):4260-9. PubMed ID: 18588281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of C-methyl-beta-D-ribofuranosyladenine nucleoside ribonucleotide reductase inhibitors.
    Franchetti P; Cappellacci L; Pasqualini M; Petrelli R; Vita P; Jayaram HN; Horvath Z; Szekeres T; Grifantini M
    J Med Chem; 2005 Jul; 48(15):4983-9. PubMed ID: 16033277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From the covalent linkage of drugs to novel inhibitors of ribonucleotide reductase: synthesis and biological evaluation of valproic esters of 3'-C-methyladenosine.
    Petrelli R; Meli M; Vita P; Torquati I; Ferro A; Vodnala M; D'Alessandro N; Tolomeo M; Del Bello F; Kusumanchi P; Franchetti P; Grifantini M; Jayaram HN; Hofer A; Cappellacci L
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5304-9. PubMed ID: 25304896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.
    Cappellacci L; Petrelli R; Franchetti P; Vita P; Kusumanchi P; Kumar M; Jayaram HN; Zhou B; Yen Y; Grifantini M
    Eur J Med Chem; 2011 May; 46(5):1499-504. PubMed ID: 21349610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibition modulates deoxyribonucleotide pools and enhances the antitumor effects of the ribonucleotide reductase inhibitor 3'-C-methyladenosine in leukaemia cells.
    Meli M; Tolomeo M; Grifantini M; Mai A; Cappellacci L; Petrelli R; Rotili D; Ferro A; Saiko P; Szekeres T; Dusonchet L
    Int J Oncol; 2011 May; 38(5):1427-36. PubMed ID: 21318222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity.
    Easmon J; Heinisch G; Pürstinger G; Langer T; Osterreicher JK; Grunicke HH; Hofmann J
    J Med Chem; 1997 Dec; 40(26):4420-5. PubMed ID: 9435912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.
    Raichurkar AV; Kulkarni VM
    J Med Chem; 2003 Oct; 46(21):4419-27. PubMed ID: 14521406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antitumor activity of 5'-deoxy-4'-thio-L-nucleosides.
    Cong L; Zhou W; Jin D; Wang J; Chen X
    Chem Biol Drug Des; 2010 Jun; 75(6):619-27. PubMed ID: 20337785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.
    Cappellacci L; Franchetti P; Pasqualini M; Petrelli R; Vita P; Lavecchia A; Novellino E; Costa B; Martini C; Klotz KN; Grifantini M
    J Med Chem; 2005 Mar; 48(5):1550-62. PubMed ID: 15743197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary SAR analysis of novel antiproliferative N(6),5'-bis-ureidoadenosine derivatives.
    Peterson MA; Oliveira M; Christiansen MA; Cutler CE
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6775-9. PubMed ID: 19850476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.
    Franchetti P; Cappellacci L; Vita P; Petrelli R; Lavecchia A; Kachler S; Klotz KN; Marabese I; Luongo L; Maione S; Grifantini M
    J Med Chem; 2009 Apr; 52(8):2393-406. PubMed ID: 19317449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities.
    Son JK; Zhao LX; Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong TC; Jeong BS; Lee CS; Lee ES
    Eur J Med Chem; 2008 Apr; 43(4):675-82. PubMed ID: 17673337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
    Tuncbilek M; Guven EB; Onder T; Cetin Atalay R
    J Med Chem; 2012 Apr; 55(7):3058-65. PubMed ID: 22409771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of 3- and 5-amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone.
    Liu MC; Lin TS; Cory JG; Cory AH; Sartorelli AC
    J Med Chem; 1996 Jun; 39(13):2586-93. PubMed ID: 8691457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and cytotoxic evaluation of substituted urea derivatives as inhibitors of human-leukemia K562 cells.
    Cao P; Huang XF; Ding H; Ge HM; Li HQ; Ruan BF; Zhu HL
    Chem Biodivers; 2007 May; 4(5):881-6. PubMed ID: 17511003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
    Jiang F; Weng Q; Sheng R; Xia Q; He Q; Yang B; Hu Y
    Arch Pharm (Weinheim); 2007 May; 340(5):258-63. PubMed ID: 17464965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of novel acyclic versions of Neplanocin A.
    Wu Y; Hong JH
    Arch Pharm (Weinheim); 2005 Nov; 338(11):517-21. PubMed ID: 16281309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Design and synthesis of 3'-methyl-furanonucleosides and their anti-tumor activities].
    Shi LH; Jin DZ; Zhou WC; Wang J; Chen XH
    Yao Xue Xue Bao; 2009 Jul; 44(7):747-53. PubMed ID: 19806914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More potent linear peptide inhibitors of mammalian ribonucleotide reductase.
    Tan C; Gao Y; Kaur J; Cooperman BS
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5301-4. PubMed ID: 15454215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.